Stocktoria
Fulgent Genetics, Inc. FLGT
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2016-09-28
Fulgent Genetics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $322.7M | $283.5M | $289.2M | $619.0M | $992.6M |
| Gross profit | $130.9M | $107.2M | $104.5M | $366.9M | $777.1M |
| R&D expense | $53.9M | $48.8M | $41.4M | $28.9M | $24.2M |
| Operating income | -$91.1M | -$73.9M | -$195.5M | $178.5M | $676.0M |
| Interest expense | — | — | — | $346,000 | $117,000 |
| Income tax | -$8.4M | -$8.1M | $1.2M | $42.1M | $174.8M |
| Net income | -$60.5M | -$42.7M | -$167.8M | $143.4M | $507.4M |
| Operating cash flow | -$101.6M | $21.1M | $27.0M | $253.5M | $538.6M |
| Free cash flow | -$124.2M | -$19.3M | $4.8M | $234.7M | $514.8M |
| Cash & equivalents | $50.2M | $55.1M | $97.5M | $79.5M | $164.9M |
| Total assets | $1.2B | $1.2B | $1.2B | $1.4B | $1.3B |
| Total liabilities | $106.8M | $90.8M | $102.0M | $116.2M | $112.8M |
| Shareholders' equity | $1.1B | $1.1B | $1.1B | $1.3B | $1.2B |
Source: SEC EDGAR filings · CIK 0001674930 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.